Robbins Paul F, Li Yong F, El-Gamil Mona, Zhao Yangbing, Wargo Jennifer A, Zheng Zhili, Xu Hui, Morgan Richard A, Feldman Steven A, Johnson Laura A, Bennett Alan D, Dunn Steven M, Mahon Tara M, Jakobsen Bent K, Rosenberg Steven A
Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
J Immunol. 2008 May 1;180(9):6116-31. doi: 10.4049/jimmunol.180.9.6116.
Single and dual amino acid substitution variants were generated in the TCR CDRs of three TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR gene-modified T cells to the cognate Ag complex were identified using a rapid RNA-based transfection system. The screening of a panel of variants of the 1G4 TCR, that recognizes a peptide corresponding to amino acid residues 157-165 of the human cancer testis Ag NY-ESO-1 (SLLMWITQC) in the context of the HLA-A02 class I allele, resulted in the identification of single and dual CDR3alpha and CDR2beta amino acid substitutions that dramatically enhanced the specific recognition of NY-ESO-1(+)/HLA-A02(+) tumor cell lines by TCR gene-modified CD4(+) T cells. Within this group of improved TCRs, a dual substitution in the 1G4 TCR CDR3alpha chain was identified that enhanced Ag-specific reactivity in gene-modified CD4(+) and CD8(+) T cells. Separate experiments on two distinct TCRs that recognize the MART-1 27-35 (AAGIGILTV) peptide/HLA-A*02 Ag complex characterized single amino acid substitutions in both TCRs that enhanced CD4(+) T cell Ag-specific reactivity. These results indicate that simple TCR substitution variants that enhance T cell function can be identified by rapid transfection and assay techniques, providing the means for generating potent Ag complex-specific TCR genes for use in the study of T cell interactions and in T cell adoptive immunotherapy.
在识别肿瘤相关抗原的三种TCR的CDR中产生了单氨基酸和双氨基酸取代变体。使用基于RNA的快速转染系统鉴定了增强TCR基因修饰的T细胞对同源抗原复合物反应性的取代。对1G4 TCR的一组变体进行筛选,该变体在HLA-A02 I类等位基因背景下识别与人癌睾丸抗原NY-ESO-1(SLLMWITQC)的氨基酸残基157-165相对应的肽,结果鉴定出单CDR3α和双CDR3α以及CDR2β氨基酸取代,这些取代显著增强了TCR基因修饰的CD4(+) T细胞对NY-ESO-1(+)/HLA-A02(+)肿瘤细胞系的特异性识别。在这组改进的TCR中,鉴定出1G4 TCR CDR3α链中的双取代,其增强了基因修饰的CD4(+)和CD8(+) T细胞中的抗原特异性反应性。对识别MART-1 27-35(AAGIGILTV)肽/HLA-A*02抗原复合物的两种不同TCR进行的单独实验,表征了两种TCR中的单氨基酸取代,这些取代增强了CD4(+) T细胞的抗原特异性反应性。这些结果表明,通过快速转染和检测技术可以鉴定出增强T细胞功能的简单TCR取代变体,为生成用于T细胞相互作用研究和T细胞过继免疫治疗的强效抗原复合物特异性TCR基因提供了手段。